Wed 8/12/2020 20:14 ET
S&P 5003380.3547.321.40%BANKS358.942.550.71%OIL42.520.150.35%BITCOIN11583.570.000.00%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Penny Stocks (THERALASE TECHNOLOGI - TLTFF)   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add TLTFF
From: 123414 (Rep: 0)Date: 01/13/2020 07:16
Forum: Penny Stocks - Msg #4263 - List TLTFF msgs Thread #674116418 (Rec: 0)
Phase 2 study: 6 patients treated.
The company is fully financed to finish StudyII.
As per 1Q2020 Company Quarterly Newsletter.

Phase II NMIBC Clinical Study Status

In 4Q2019, Theralase filed an Investigational New Drug ("IND") application to the Food and Drug Administration ("FDA") for a pivotal Phase II NonMuscle Invasive Bladder Cancer ("NMIBC") clinical study. The IND is currently on Full Clinical Hold pending a response by Theralase, which is expected in 1Q2020.

Pending FDA acceptance of Theralase's response, Theralase will commence onboarding clincial study sites in the United States.

In the mean time, Theralase is proceeding with patient enrollment and study site onboarding in Canada.
University Health Network ("UHN")
The Phase II NMIBC clinical study ("Study II") has successfully launched in Canada, with 3 Canadian centres open for enrollment and treatment of patients.

1.(Toronto, ON) - 5 patients treated
2. McGill University Health Centre ("MUHC")(Montreal, QC) - 1 patient treated
3. London Health Sciences Centre ("LHSC") (London, ON) - 0 patient treated

To date, 6 patients have been treated.


Financial Highlights:
As per 1Q2020 Company Quarterly Newsletter.

As of November 29, 2019, Theralase has 14.98M in cash and zero debt, except for trade payables. The company is fully financed to finish StudyII.


Phase 1 (completed study) patients 5 and 6 will be hitting 24 month treatment anniversary's. Both of these patients were cancer free 18 months after single treatment.

If both patients remain cancer free after 24 months from a single treatment, the company will have unprecedented data points.

Phase 1 patients 5 and 6 were respectfully initially treated on Jan 10 and Feb 7, 2018.


[b]Theralase Technologies has a 256 per cent upside[/b], says Mackie Research


In Sept stock was around .16 - .18 cents.

Currently in January it's at about .25 after an expected pullback from a recent high of .295 in 2020.


Link to company PRs


Potential upcoming PRs

- announcement(s) of new ph1 trial(s) for new indication(s) (additional cancer types)
- FDA approval of US-based test sites for ph2 NMIBC trials
- additional results from ph 1b trials (over longer time periods)
- JV or other interest from big pharma
- more Canada-based ph2 test sites
- more enrolled patients

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser 123414: Reward | Watch | IgnoreTLTFF: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add TLTFF | About Us | Agreement & Disclaimer | Privacy | Twitter
© 2020-, Inc.